Population Pharmacokinetics of Telavancin in Healthy Subjects and Patients with Infections

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2012 Jan 19

PMID 22252798

Citations 13

Authors

Emil Samara

Jeng-Pyng Shaw

Steven L Barriere

Shekman L Wong

Philip Worboys

Affiliations

Soon will be listed here.

Abstract

A population pharmacokinetic model of telavancin, a lipoglycopeptide antibiotic, was developed and used to identify sources of interindividual variability. Data were obtained from healthy subjects (seven phase 1 studies), patients with complicated skin and skin structure infections (cSSSI; two phase 2 and two phase 3 studies), and patients with hospital-acquired pneumonia (HAP; two phase 3 studies). A two-compartment open model with zero-order input best fit the telavancin data from healthy individuals and patients with cSSSI or HAP. Telavancin clearance was highly correlated with renal function and, to a lesser extent, with body weight. Other covariates were related to at least one parameter in cSSSI (gender, bacterial eradication, and surgery) or HAP (age of ≥ 75 years) but did not markedly affect exposure. These analyses support current dosing recommendations for telavancin based on patient weight and renal function.

Citing Articles

Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital.

Diggs F, Edwards J, Garza K, Hassoun A, Durham S Antimicrob Agents Chemother. 2021; 66(1):e0160321.

PMID: 34662182 PMC: 8765302. DOI: 10.1128/AAC.01603-21.

Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity.

Pai M Clin Pharmacol Ther. 2021; 109(4):942-951.

PMID: 33523485 PMC: 8855475. DOI: 10.1002/cpt.2181.

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.

Wu W, Ke M, Ye L, Lin C Eur J Clin Pharmacol. 2021; 77(7):989-998.

PMID: 33447912 PMC: 7808764. DOI: 10.1007/s00228-020-03072-y.

Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.

Kidd J, Sakon C, Oleksiuk L, Cies J, Pettit R, Nicolau D Antimicrob Agents Chemother. 2019; 64(1).

PMID: 31685468 PMC: 7187619. DOI: 10.1128/AAC.01914-19.

Evaluation of treatment options for methicillin-resistant infections in the obese patient.

Narayanan N, Adams C, Kubiak D, Cheng S, Stoianovici R, Kagan L Infect Drug Resist. 2019; 12:877-891.

PMID: 31114267 PMC: 6490236. DOI: 10.2147/IDR.S196264.

References

Hegde S, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J . Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother. 2004; 48(8):3043-50. PMC: 478526. DOI: 10.1128/AAC.48.8.3043-3050.2004. View

Stryjewski M, ORiordan W, Lau W, Pien F, Dunbar L, Vallee M . Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005; 40(11):1601-7. DOI: 10.1086/429914. View

Wong S, Goldberg M, Ballow C, Kitt M, Barriere S . Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010; 30(2):136-43. DOI: 10.1592/phco.30.2.136. View

Krause K, Renelli M, Difuntorum S, Wu T, Debabov D, Benton B . In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008; 52(7):2647-52. PMC: 2443888. DOI: 10.1128/AAC.01398-07. View

Higgins D, Chang R, Debabov D, Leung J, Wu T, Krause K . Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005; 49(3):1127-34. PMC: 549257. DOI: 10.1128/AAC.49.3.1127-1134.2005. View

Rubinstein E, Lalani T, Corey G, Kanafani Z, Nannini E, Rocha M . Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2010; 52(1):31-40. PMC: 3060890. DOI: 10.1093/cid/ciq031. View

Gotfried M, Shaw J, Benton B, Krause K, Goldberg M, Kitt M . Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2007; 52(1):92-7. PMC: 2223919. DOI: 10.1128/AAC.00875-07. View

Sun H, Duchin K, Nightingale C, Shaw J, Seroogy J, Nicolau D . Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006; 50(2):788-90. PMC: 1366897. DOI: 10.1128/AAC.50.2.788-790.2006. View

Goldberg M, Wong S, Shaw J, Kitt M, Barriere S . Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010; 30(8):806-11. DOI: 10.1592/phco.30.8.806. View

10.

Lodise T, Butterfield J, Hegde S, Samara E, Barriere S . Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother. 2012; 56(4):2062-6. PMC: 3318336. DOI: 10.1128/AAC.00383-11. View

11.

Shaw J, Seroogy J, Kaniga K, Higgins D, Kitt M, Barriere S . Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2004; 49(1):195-201. PMC: 538848. DOI: 10.1128/AAC.49.1.195-201.2005. View

12.

Lunde C, Hartouni S, Janc J, Mammen M, Humphrey P, Benton B . Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009; 53(8):3375-83. PMC: 2715647. DOI: 10.1128/AAC.01710-08. View

13.

Battistini N, Virgili F, Severi S, Brambilla P, Manzoni P, Beccaria L . Relative expansion of extracellular water in obese vs. normal children. J Appl Physiol (1985). 1995; 79(1):94-6. DOI: 10.1152/jappl.1995.79.1.94. View

14.

Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J . Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004; 44(7):689-95. DOI: 10.1177/0091270004266620. View

15.

Leadbetter M, Adams S, Bazzini B, Fatheree P, Karr D, Krause K . Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo). 2004; 57(5):326-36. DOI: 10.7164/antibiotics.57.326. View

16.

Stryjewski M, Graham D, Wilson S, ORiordan W, Young D, Lentnek A . Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008; 46(11):1683-93. DOI: 10.1086/587896. View

17.

Waki M, Kral J, Mazariegos M, Wang J, Pierson Jr R, Heymsfield S . Relative expansion of extracellular fluid in obese vs. nonobese women. Am J Physiol. 1991; 261(2 Pt 1):E199-203. DOI: 10.1152/ajpendo.1991.261.2.E199. View

18.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

19.

Wong S, Barriere S, Kitt M, Goldberg M . Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008; 62(4):780-3. DOI: 10.1093/jac/dkn273. View

20.

Goldberg M, Wong S, Shaw J, Kitt M, Barriere S . Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2009; 30(1):35-42. DOI: 10.1592/phco.30.1.35. View